Multidisciplinary collaboration in gallbladder carcinoma treatment: A case report and literature review

Zou,Zheng‑Yun; Yan,Jing; Zhuge,Yu‑Zheng; Chen,Jun; Qian,Xiao‑Ping; Liu,Bao‑Rui

doi:10.3892/ol.2016.5020

Multidisciplinary collaboration in gallbladder carcinoma treatment: A case report and literature review

Authors:
- Zheng‑Yun Zou
- Jing Yan
- Yu‑Zheng Zhuge
- Jun Chen
- Xiao‑Ping Qian
- Bao‑Rui Liu
View Affiliations

Affiliations: Comprehensive Cancer Center, Drum‑Tower Hospital, Medical School of Nanjing University, Nanjing, Jiangsu 210008, P.R. China, Gastrointestinal Endoscopy Center, Drum‑Tower Hospital, Medical School of Nanjing University, Nanjing, Jiangsu 210008, P.R. China, Department of Pathology, Drum‑Tower Hospital, Medical School of Nanjing University, Nanjing, Jiangsu 210008, P.R. China
Published online on: August 16, 2016 https://doi.org/10.3892/ol.2016.5020
Pages: 2696-2701

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gallbladder carcinoma (GBC) is a rare and highly aggressive disease. The diagnosis of this cancer is difficult due to its occult onset. Hence, GBC is often detected late and at an advanced stage. Although physicians and researchers are continually working to improve the treatment for advanced‑stage disease, GBC is usually associated with short survival times. The present study describes a case of GBC that was first diagnosed with accompanying cholecystolithiasis at the time of cholecystectomy. Cancer relapse occurred 1.5 years after the cholecystectomy. Multidisciplinary collaboration was involved in the decision‑making process for the treatment of this aggressive recurrence, and the survival time was successfully extended to 26 months. Importantly, high‑grade intraepithelial neoplasia and positive margins had previously been detected post‑cholecystectomy at a different institution, but were ignored. Relapse may have been preventable had the cancer been diagnosed when it was initially observed. Taken together, these findings suggest that multidisciplinary collaboration should be considered for the management of advanced GBC, whereby patients will benefit from improved survival times. Furthermore, it is recommended that samples obtained from patients undergoing cholecystectomy should more carefully analyzed for evidence of cancerous or precancerous tissues.

View Figures

View References

1	Randi G, Malvezzi M, Levi F, Ferlay J, Negri E, Franceschi S and La Vecchia C: Epidemiology of biliary tract cancers: An update. Ann Oncol. 20:146–159. 2009. View Article : Google Scholar : PubMed/NCBI
2	Hezel AF and Zhu AX: Systemic therapy for biliary tract cancers. Oncologist. 13:415–423. 2008. View Article : Google Scholar : PubMed/NCBI
3	Donohue JH, Stewart AK and Menck HR: The national cancer data base report on carcinoma of the gallbladder, 1989–1995. Cancer. 83:2618–2628. 1998. View Article : Google Scholar : PubMed/NCBI
4	Eckel F and Schmid RM: Chemotherapy in advanced biliary tract carcinoma: A pooled analysis of clinical trials. Br J Cancer. 96:896–902. 2007. View Article : Google Scholar : PubMed/NCBI
5	Watanabe Y, Goto H, Hirooka Y, Itoh A, Taki T, Hayakawa S, Hayakawa T, Naitoh Y, Ohhashi K, Yamao K and Furukawa T: Transpapillary biopsy in gallbladder disease. Gastrointest Endosc. 51:76–79. 2000. View Article : Google Scholar : PubMed/NCBI
6	Duffy A, Capanu M, Abou-Alfa GK, Huitzil D, Jarnagin W, Fong Y, D'Angelica M, Dematteo RP, Blumgart LH and O'Reilly EM: Gallbladder cancer (GBC): 10-year experience at memorial Sloan-Kettering cancer centre (MSKCC). J Surg Oncol. 98:485–489. 2008. View Article : Google Scholar : PubMed/NCBI
7	National Comprehensive Cancer Network, . NCCN Clinical Practice Guidelines in Oncology. Hepatobiliary Cancers (version 2, 2016). https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdfAccessed. July 6–2016
8	Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL and Trotti A: AJCC Cancer Staging HandbookFrom the AJCC Cancer Staging Manual. 7th. Springer; New York: 2010
9	Lazcano-Ponce EC, Miquel JF, Muñoz N, Herrero R, Ferrecio C, Wistuba II, de Ruiz P Alonso, Urista G Aristi and Nervi F: Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin. 51:349–364. 2001. View Article : Google Scholar : PubMed/NCBI
10	Sheth S, Bedford A and Chopra S: Primary gallbladder cancer: Recognition of risk factors and the role of prophylactic cholecystectomy. Am J Gastroenterol. 95:1402–1410. 2000. View Article : Google Scholar : PubMed/NCBI
11	Bosman FT, Carneiro F, Hruban RH and Threise ND: WHO Classification of Tumours of the Digestive System. 4th. IARC Press; Lyon: 2010
12	Shimizu T, Arima Y, Yokomuro S, Yoshida H, Mamada Y, Nomura T, Taniai N, Aimoto T, Nakamura Y, Mizuguchi Y, et al: Incidental gallbladder cancer diagnosed during and after laparoscopic cholecystectomy. J Nippon Med Sch. 73:136–140. 2006. View Article : Google Scholar : PubMed/NCBI
13	Gebbia N, Verderame F, Di Leo R, Santangelo D, Cicero G, Valerio MR, Arcara C, Badalamenti G, Fulfaro F and Carreca I: A phase II study of oxaliplatin (O) and gemcitabine (G) first line chemotherapy in patients with advanced biliary tract cancers. J Clin Oncol. 23(suppl): abstract 4132. 2005.
14	Kuriyama H, Kawana K, Taniguchi R, Jono F, Sakai E, Okubo H, Suzuki H, Kobayashi S, Murata Y, Inamori M, et al: Single-agent gemcitabine in elderly patients with unresectable biliary tract cancer. Hepatogastroenterology. 58:26–30. 2011.PubMed/NCBI
15	Ueno H, Okusaka T, Ikeda M, Takezako Y and Morizane C: Phase II study of S-1 in patients with advanced biliary tract cancer. Br J Cancer. 91:1769–1774. 2004. View Article : Google Scholar : PubMed/NCBI
16	Harder J, Riecken B, Kummer O, Lohrmann C, Otto F, Usadel H, Geissler M, Opitz O and Henss H: Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer. Br J Cancer. 95:848–852. 2006. View Article : Google Scholar : PubMed/NCBI
17	Williams KJ, Picus J, Trinkhaus K, Fournier CC, Suresh R, James JS and Tan BR: Gemcitabine with carboplatin for advanced biliary tract cancers: A phase II single institution study. HPB (Oxford). 12:418–426. 2010. View Article : Google Scholar : PubMed/NCBI
18	Petera J, Kasaová L, Paluska P, Sirák I, Jansa J, Macingová Z, Dvorák J and Soumarova R: Intensity-modulated radiotherapy in the treatment of subhepatic carcinomas. Hepatogastroenterology. 58:331–335. 2011.PubMed/NCBI
19	Beltrán M Bonet, Roth AD, Mentha G and Allal AS: Adjuvant radio-chemotherapy for extrahepatic biliary tract cancers. BMC Cancer. 11:2672011. View Article : Google Scholar : PubMed/NCBI
20	Yoshikawa D, Ojima H, Iwasaki M, Hiraoka N, Kosuge T, Kasai S, Hirohashi S and Shibata T: Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer. 98:418–425. 2008. View Article : Google Scholar : PubMed/NCBI
21	Gruenberger B, Schueller J, Heubrandtner U, Wrba F, Tamandl D, Kaczirek K, Roka R, Freimann-Pircher S and Gruenberger T: Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: A phase 2 study. Lancet Oncol. 11:1142–1148. 2010. View Article : Google Scholar : PubMed/NCBI
22	Chang PY, Cheng MF, Lee HS, Hsieh CB and Yao NS: Preliminary experience of cetuximab in the treatment of advanced-stage biliary tract cancer. Onkologie. 33:45–47. 2010. View Article : Google Scholar : PubMed/NCBI
23	Zitvogel L, Apetoh L, Ghiringhelli F, André F, Tesniere A and Kroemer G: The anticancer immune response: Indispensable for therapeutic success? J Clin Invest. 118:1991–2001. 2008. View Article : Google Scholar : PubMed/NCBI
24	Correale P, Cusi MG, Tsang KY, Del Vecchio MT, Marsili S, Placa ML, Intrivici C, Aquino A, Micheli L, Nencini C, et al: Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients. J Clin Oncol. 23:8950–8958. 2005. View Article : Google Scholar : PubMed/NCBI
25	O'Day SJ, Atkins MB, Boasberg P, Wang HJ, Thompson JA, Anderson CM, Gonzalez R, Lutzky J, Amatruda T, Hersh EM and Weber JS: Phase II multicenter trial of maintenance biotherapy after induction concurrent biochemotherapy for patients with metastatic melanoma. J Clin Oncol. 27:6207–6212. 2009. View Article : Google Scholar : PubMed/NCBI